mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.
- 1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
- 2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou Medical College, Soochow University, Suzhou, 215123, China.
- 3CSPC Pharmaceutical Group Co., Ltd., 896 East Zhongshan Road, Shijiazhuang 050035, China.
Abstract
Background
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for management of relapsed/refractory acute myeloid leukemia (R/R AML). Safety and preliminary activity of CD38-targeted CAR-T cells in R/R AML were demonstrated in our prior study; however, relapse with CD38-positive blasts persisted, which was partly associated with insufficient effector function and persistence of CAR-T cells. Given that CAR-T cell hypofunction is promoted by inadequate antigen stimulation, a lipid nanoparticle-delivered CD38 mRNA vaccine was developed to enhance CD38 CAR-T cell efficacy via exogenous antigen presentation.Methods
The CD38 mRNA-LNP vaccine was prepared, and its biodistribution profile and tolerability were evaluated in BALB/c mice. The capacity of this vaccine to augment the activation, proliferative capacity, memory subset distribution, cytokine secretion, and antileukemic efficacy of CD38-knockout CAR-T cells (Ko-38CAR) was systematically assessed in vitro. Transcriptomic and ATAC-seq analyses were employed to delineate the underlying molecular regulatory networks. In vivo antitumor efficacy was validated in a THP-1 AML xenograft model.Results
The vaccine (107 nm, 91.67% encapsulation) exhibited splenic APC tropism and induced pulsatile CD38 expression that peaked at 24 h and declined markedly by 48 h. Activation, proliferation, cytotoxicity, and memory differentiation of Ko-38CAR cells were dose-dependently augmented by the vaccine. Furthermore, the vaccine promoted the activation of polyamine metabolism (e.g., ODC1), JAK-STAT and MAPK signaling pathways, upregulated BCL2 expression, and enhanced chromatin accessibility of cell cycle and effector genes in CAR-T cells. In vivo, vaccine administration promoted CAR-T cell expansion, improved tumor control, and prolonged survival.Conclusions
CD38 mRNA-LNP vaccine can efficiently deliver pulsatile CD38 antigen to splenic APCs and augment the proliferation, effector function, and persistence of CD38 CAR-T cells through dual CAR and costimulatory signaling, which may represent a promising strategy to overcome CAR-T cell dysfunction in R/R AML.
Related
- Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.
- Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML
- Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Hypofractionated Total Marrow and Lymphoid Irradiation for Relapsed/Refractory Leukemia Using Helical Tomotherapy: Workflow and Dosimetric Analysis
- Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.
BibTeX
@article{lu2026mrnadendritic,
title = {{mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.}},
author = {Yu Lu and Xin Cai and Yanhui Li and Yuyuan Lv and Yutong Tang and Yuanyuan Li and Jiazi Zhou and Ailin Zhang and Pengchen Gu and Ziyi Hao and Qingya Cui and Jianhong Chu and Depei Wu and Xiaowen Tang},
journal = {Theranostics},
year = {2026},
month = aug,
doi = {10.7150/thno.139339},
url = {https://europepmc.org/article/MED/42909370},
note = {CC BY},
}
RIS
TY - JOUR
TI - mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.
AU - Yu Lu
AU - Xin Cai
AU - Yanhui Li
AU - Yuyuan Lv
AU - Yutong Tang
AU - Yuanyuan Li
AU - Jiazi Zhou
AU - Ailin Zhang
AU - Pengchen Gu
AU - Ziyi Hao
AU - Qingya Cui
AU - Jianhong Chu
AU - Depei Wu
AU - Xiaowen Tang
PY - 2026
DA - 2026/08/24
JO - Theranostics
DO - 10.7150/thno.139339
UR - https://europepmc.org/article/MED/42909370
AB - Background Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for management of relapsed/refractory acute myeloid leukemia (R/R AML). Safety and preliminary activity of CD38-targeted CAR-T cells in R/R AML were demonstrated in our prior study; however, relapse with CD38-positive blasts persisted, which was partly associated with insufficient effector function and persistence of CAR-T cells. Given that CAR-T cell hypofunction is promoted by inadequate antigen stimulation, a lipid nanoparticle-delivered CD38 mRNA vaccine was developed to enhance CD38 CAR-T cell efficacy via exogenous antigen presentation.Methods The CD38 mRNA-LNP vaccine was prepared, and its biodistribution profile and tolerability were evaluated in BALB/c mice. The capacity of this vaccine to augment the activation, proliferative capacity, memory subset distribution, cytokine secretion, and antileukemic efficacy of CD38-knockout CAR-T cells (Ko-38CAR) was systematically assessed in vitro. Transcriptomic and ATAC-seq analyses were employed to delineate the underlying molecular regulatory networks. In vivo antitumor efficacy was validated in a THP-1 AML xenograft model.Results The vaccine (107 nm, 91.67% encapsulation) exhibited splenic APC tropism and induced pulsatile CD38 expression that peaked at 24 h and declined markedly by 48 h. Activation, proliferation, cytotoxicity, and memory differentiation of Ko-38CAR cells were dose-dependently augmented by the vaccine. Furthermore, the vaccine promoted the activation of polyamine metabolism (e.g., ODC1), JAK-STAT and MAPK signaling pathways, upregulated BCL2 expression, and enhanced chromatin accessibility of cell cycle and effector genes in CAR-T cells. In vivo, vaccine administration promoted CAR-T cell expansion, improved tumor control, and prolonged survival.Conclusions CD38 mRNA-LNP vaccine can efficiently deliver pulsatile CD38 antigen to splenic APCs and augment the proliferation, effector function, and persistence of CD38 CAR-T cells through dual CAR and costimulatory signaling, which may represent a promising strategy to overcome CAR-T cell dysfunction in R/R AML.
SN - 1838-7640
ER -